Seminars in Nuclear Medicine
Volume 32, Issue 4 , Pages 293-321, October 2002

Positron emission tomography imaging in nonmalignant thoracic disorders

  • Abass Alavi

      Affiliations

    • Division of Nuclear Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA USA
    • Division of Nuclear Medicine, West Virginia University, Morgantown, WV. USA
    • Corresponding Author InformationAddress reprint requests to Abass Alavi, Division of Nuclear Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104
  • ,
  • Naresh Gupta

      Affiliations

    • Division of Nuclear Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA USA
    • Division of Nuclear Medicine, West Virginia University, Morgantown, WV. USA
  • ,
  • Jean-Louis Alberini

      Affiliations

    • Division of Nuclear Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA USA
    • Division of Nuclear Medicine, West Virginia University, Morgantown, WV. USA
  • ,
  • Marc Hickeson

      Affiliations

    • Division of Nuclear Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA USA
    • Division of Nuclear Medicine, West Virginia University, Morgantown, WV. USA
  • ,
  • Lars-Eric Adam

      Affiliations

    • Division of Nuclear Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA USA
    • Division of Nuclear Medicine, West Virginia University, Morgantown, WV. USA
  • ,
  • Peeyush Bhargava

      Affiliations

    • Division of Nuclear Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA USA
    • Division of Nuclear Medicine, West Virginia University, Morgantown, WV. USA
  • ,
  • Hongming Zhuang

      Affiliations

    • Division of Nuclear Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA USA
    • Division of Nuclear Medicine, West Virginia University, Morgantown, WV. USA

The role of the fluorodeoxyglucose (FDG) technique positron emission tomography (PET) is well established in the management of patients with lung cancer. Increasingly, it is becoming evident that FDG-PET can be effectively employed to diagnose a variety of benign pulmonary disorders. Knowledge of such applications further expands the domain of this powerful modality and further improves the ability to differentiate benign from malignant diseases of the chest. We describe pertinent technical factors that substantially contribute to optimal imaging of the thoracic structures. Particularly, the complementary role of attenuation correction (AC) to that of non-AC images is emphasized. We further outline the need for and the state of the art for co-registration of PET and anatomic images for diagnostic and therapeutic purposes. We then review patterns of physiologic uptake of FDG in thoracic structures, including the lung, the heart, the aorta and large arteries, esophagus, thymus, trachea, thoracic muscles, bone marrow, and joints and alterations following radiation therapy to the thorax. A great deal of information is provided with regard to differentiating benign from malignant nodules and in particular, we emphasize the role of dual time point imaging and partial volume correction for accurate assessment of such lesions. Following a brief review of the diagnostic issues related to the assessment of mediastinal adenopathies, the role of FDG-PET imaging in environment-induced lung diseases, including pneumoconiosis, smoking, and asthma are described. A large body of information is provided about the role of this technology in the management of patients with suspected infection and inflammation of the lungs such as acquired immunodeficiency syndrome, fever of unknown origin, sarcoidosis, chronic granulomatous disease and monitoring the disease process and response to therapy. Finally, the value of FDG-PET in differentiating benign from malignant diseases of the pleura including asbestosis-related disorders is described at the conclusion of this comprehensive review.

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0001-2998(02)80020-4

doi:10.1053/snuc.2002.127291

Seminars in Nuclear Medicine
Volume 32, Issue 4 , Pages 293-321, October 2002